These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 22797920

  • 1. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
    Azijli K, Yuvaraj S, Peppelenbosch MP, Würdinger T, Dekker H, Joore J, van Dijk E, Quax WJ, Peters GJ, de Jong S, Kruyt FA.
    J Cell Sci; 2012 Oct 01; 125(Pt 19):4651-61. PubMed ID: 22797920
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
    Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM.
    Cancer Res; 2005 Jul 15; 65(14):6275-81. PubMed ID: 16024629
    [Abstract] [Full Text] [Related]

  • 8. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ.
    Oncol Rep; 2007 Jan 15; 17(1):175-84. PubMed ID: 17143496
    [Abstract] [Full Text] [Related]

  • 9. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.
    Chen W, Wang X, Zhuang J, Zhang L, Lin Y.
    Carcinogenesis; 2007 Oct 15; 28(10):2114-21. PubMed ID: 17548900
    [Abstract] [Full Text] [Related]

  • 10. Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.
    Lan Y, Liu X, Zhang R, Wang K, Wang Y, Hua ZC.
    Biometals; 2013 Apr 15; 26(2):241-54. PubMed ID: 23378009
    [Abstract] [Full Text] [Related]

  • 11. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S, Liu X, Yue P, Schönthal AH, Khuri FR, Sun SY.
    Mol Pharmacol; 2007 Nov 15; 72(5):1269-79. PubMed ID: 17684158
    [Abstract] [Full Text] [Related]

  • 12. Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells.
    Oh S, Kwon D, Lee HJ, Kim J, Lee E.
    Apoptosis; 2010 Dec 15; 15(12):1517-28. PubMed ID: 20623193
    [Abstract] [Full Text] [Related]

  • 13. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 14. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
    Ouyang W, Yang C, Zhang S, Liu Y, Yang B, Zhang J, Zhou F, Zhou Y, Xie C.
    Int J Oncol; 2013 Feb 01; 42(2):699-711. PubMed ID: 23258590
    [Abstract] [Full Text] [Related]

  • 15. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
    Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB.
    Cancer Res; 2006 Jun 01; 66(11):5542-8. PubMed ID: 16740687
    [Abstract] [Full Text] [Related]

  • 16. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 17. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
    Yang J, Chen SZ.
    Yao Xue Xue Bao; 2010 Oct 15; 45(10):1247-53. PubMed ID: 21348302
    [Abstract] [Full Text] [Related]

  • 18. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
    Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P.
    J Pharmacol Exp Ther; 2014 Mar 15; 348(3):360-71. PubMed ID: 24345465
    [Abstract] [Full Text] [Related]

  • 19. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.
    Ouyang W, Yang C, Liu Y, Xiong J, Zhang J, Zhong Y, Zhang G, Zhou F, Zhou Y, Xie C.
    Int J Oncol; 2011 Dec 15; 39(6):1577-86. PubMed ID: 21769428
    [Abstract] [Full Text] [Related]

  • 20. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.